Published in Thromb Haemost on June 28, 1982
Spherical splines for scalp potential and current density mapping. Electroencephalogr Clin Neurophysiol (1989) 6.17
Stimulus specificity of phase-locked and non-phase-locked 40 Hz visual responses in human. J Neurosci (1996) 4.68
Comprehensive compilation of empirical ultrasonic properties of mammalian tissues. J Acoust Soc Am (1978) 3.96
Induced gamma-band activity during the delay of a visual short-term memory task in humans. J Neurosci (1998) 3.35
Oscillatory gamma-band (30-70 Hz) activity induced by a visual search task in humans. J Neurosci (1997) 3.16
The Scottish perinatal mortality survey. Br Med J (1979) 2.98
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol (2000) 2.58
Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet (2001) 2.43
Oscillatory synchrony between human extrastriate areas during visual short-term memory maintenance. J Neurosci (2001) 2.08
A theoretical justification of the average reference in topographic evoked potential studies. Electroencephalogr Clin Neurophysiol (1985) 2.00
Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther (2005) 1.95
Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 1.94
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol (1995) 1.93
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med (1983) 1.85
Mapping of scalp potentials by surface spline interpolation. Electroencephalogr Clin Neurophysiol (1987) 1.84
Specific tonotopic organizations of different areas of the human auditory cortex revealed by simultaneous magnetic and electric recordings. Electroencephalogr Clin Neurophysiol (1995) 1.76
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer (1984) 1.72
Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost (2009) 1.68
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (2001) 1.67
Antithrombotic therapy for venous thromboembolic disease. Chest (1998) 1.67
Pathophysiology of endotoxin shock in the primate. Am J Obstet Gynecol (1970) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol (2001) 1.59
Secondhand smoke exposure and survival following acute coronary syndrome: prospective cohort study of 1261 consecutive admissions among never-smokers. Heart (2009) 1.57
SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res (2000) 1.55
Sustained and transient oscillatory responses in the gamma and beta bands in a visual short-term memory task in humans. Vis Neurosci (1999) 1.52
Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol (1995) 1.52
Team triage improves emergency department efficiency. Emerg Med J (2004) 1.49
Compilation of empirical ultrasonic properties of mammalian tissues. II. J Acoust Soc Am (1980) 1.49
Diabetic control in 102 insulin-treated out-patients. Diabetologia (1980) 1.47
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood (1984) 1.44
Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb Haemost (1993) 1.44
A European view on the North American fifth consensus on antithrombotic therapy. Chest (2000) 1.43
The role of fibroblasts in organization and degradation of a fibrin clot. J Lab Clin Med (1991) 1.42
Reversibility of thrombin-induced decrease in platelet glycoprotein Ib function. Br J Haematol (1993) 1.40
Cerebral infarction and familial protein S deficiency. Stroke (1990) 1.39
Rapid aequorin loading into platelets in the presence of DMSO--characteristics of the responses (changes in light transmission and in calcium) to various agonists. Thromb Haemost (1991) 1.38
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A (1998) 1.37
Scalp current density mapping: value and estimation from potential data. IEEE Trans Biomed Eng (1987) 1.37
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37
Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer (1996) 1.36
Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood (1993) 1.35
Ultrasonic absorption and attenuation in mammalian tissues. Ultrasound Med Biol (1979) 1.35
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem (1986) 1.33
Letter: Correlation of echographic visualizability of tissue with biological composition and physiological state. J Acoust Soc Am (1973) 1.32
Threshold ultrasonic dosages for structural changes in the mammalian brain. J Acoust Soc Am (1970) 1.29
Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood (1987) 1.29
Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost (1995) 1.28
The association of center performance evaluations and kidney transplant volume in the United States. Am J Transplant (2013) 1.28
Ultrasonic threshold dosages for the mammalian central nervous system. IEEE Trans Biomed Eng (1971) 1.24
Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost (1984) 1.23
[Coagulation disorders after reinjection of concentrated ascitic fluid. Preliminary study]. Med Chir Dig (1973) 1.22
Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ (1989) 1.20
Small abnormal echos after mitral valve replacement with bileaflet mechanical prostheses: predisposing factors and effect on thromboembolism. J Heart Valve Dis (1993) 1.19
Combined EEG and MEG recordings of visual 40 Hz responses to illusory triangles in human. Neuroreport (1997) 1.19
[Incidence of intramural digestive system hematoma in anticoagulation. Epidemiologic study and clinical aspects of 59 cases observed in Switzerland (1970-1975)]. Schweiz Med Wochenschr (1983) 1.19
Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res (2001) 1.18
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost (1996) 1.17
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol (1997) 1.17
Multiple supratemporal sources of magnetic and electric auditory evoked middle latency components in humans. Cereb Cortex (2001) 1.17
Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemost (1984) 1.16
Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin). Blood (1987) 1.16
Cortical mapping of gamma oscillations in areas V1 and V4 of the macaque monkey. Vis Neurosci (2002) 1.15
Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci (2003) 1.12
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost (1989) 1.12
A robust sensor-selection method for P300 brain-computer interfaces. J Neural Eng (2011) 1.11
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer (1998) 1.11
[Value of the platelet count using electronic counter]. Pathol Biol (Paris) (1970) 1.11
Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther (1998) 1.10
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry (2001) 1.10
Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood (1982) 1.10
Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med (1986) 1.10
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Separate representation of stimulus frequency, intensity, and duration in auditory sensory memory: an event-related potential and dipole-model analysis. J Cogn Neurosci (1995) 1.09
Glycosylated haemoglobin concentrations and clinitest results in insulin-dependent diabetes. Lancet (1977) 1.09
Complications following total knee replacement. Clin Orthop Relat Res (1977) 1.09
Scalp current density fields: concept and properties. Electroencephalogr Clin Neurophysiol (1988) 1.09
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol (2001) 1.08
Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost (1999) 1.08